Key Takeaways MRK launched a restructuring plan to cut 3B in annual costs by 2027 through job and real estate reductions.Savings will be reinvested into high-growth pipeline areas as MRK seeks to diversify beyond Keytruda.MRK plans to launch ~20 new drugs, backed by M&A deals like the 10B Verona buyout and Chinese biotech pacts .Along with its second-quarter results on July 29, Merck (MRK) announced a new multi-year optimization initiative, which is expected to save $3 billion in annual costs by the end o ...